Shots:
- Tolerance Bio has entered into an exclusive license agreement with Tanabe Pharma for MT-2990, an anti-IL-33 monoclonal antibody, across all indications
- Tanabe Pharma has granted Tolerance Bio worldwide development & manufacturing rights, and ex-Japan exclusive commercialization rights for MT-2990 (TLB-33), while Tanabe will retain commercialization rights in Japan
- As per the deal, Tanabe will receive potential development & sales milestone payments of ~$560M, as well as equity consideration & tiered royalties on net sales
Ref: Businesswire | Image: Tolerance Bio & Tanabe Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
